Genmab and AbbVie Announce Broad Oncology Collaboration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Genmab A/S (GMAB) PT Raised to $39 at SunTrust; 'AbbVie Deal Favorably on Several Counts'
June 10, 2020 1:16 PM EDTSunTrust analyst Asthika Goonewardene raised the price target on Genmab A/S (NASDAQ: GMAB) to $39.00 (from $36.00) while maintaining a Buy rating.
The analyst commented, "We view GMAB's deal with AbbVie (ABBV, NR) favorably on several counts. We think: (1) it puts a strong commercial partner in... More
